Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Thromb Res. 2016 Jan 5;139:29–37. doi: 10.1016/j.thromres.2016.01.002

Table 4a. Multivariable Analysis for Predictors of Venous Thromboembolism in Cancer Patients.

Characteristic OR 95% CI* P-Value*
Two-fold increase in Cancer site VTE risk score 1.37 1.09 1.71 0.007
Lymphoma: Low Grade 0.26 0.09 0.70 0.008
Lymphoma: Intermediate or High Grade 1.42 0.50 4.03 0.51
Myeloproliferative neoplasm 38.99 8.72 174.26 <.001
Stage 2 or 3 or 4 2.18 1.56 3.02 <.001
Metastasis to liver 2.70 1.69 4.31 <.001
Chemotherapy use within 92 days 1.81 1.17 2.81 0.008
Progestin use within 92 days 2.13 1.07 4.25 0.032
Body mass index (BMI) (Reference: 18.5-25 kg/m2)
 BMI <18.5 kg/m2 (Underweight) 1.93 1.02 3.66 0.044
 BMI 25-30 kg/m2 (Overweight) 1.10 0.76 1.61 0.61
 BMI 30-35 kg/m2 (Obese class I) 1.67 0.98 2.86 0.062
 BMI ≥35 kg/m2 (Obese class II-III) 3.97 1.48 10.66 0.006
Location of onset of VTE (Reference: Community)
 Nursing home 4.71 2.01 11.04 <.001
 Hospitalized within 92 days 3.89 2.53 5.97 <.001
 Hospitalized 7.91 4.44 14.10 <.001
CV catheter use within 92 days 8.53 2.76 26.40 <.001
Any infection within 92 days 1.71 1.19 2.45 0.004
*

95% Confidence intervals are calculated using the robust sandwich estimate of Lin and Wei [54] for the covariance and standard error. P-values are Wald p-values from the conditional logistic model using the robust sandwich estimate.